<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551133</url>
  </required_header>
  <id_info>
    <org_study_id>208</org_study_id>
    <nct_id>NCT02551133</nct_id>
  </id_info>
  <brief_title>Comparison of Dexamethasone Doses on Persistent Postmastectomy Pain</brief_title>
  <official_title>Comparison of the Two Different Doses of Dexamethasone on Persistent Mastectomy Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mustafa Kemal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mustafa Kemal University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of dexamethasone on persistent surgical pain after mastectomy
      operations. Half of the participants will receive 0.1 mg/kg dexamethasone and the other half
      will receive 0.2 mg/kg dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most frequent malignancy of middle age women (%32) and causes 19% of
      cancer-related deaths. Acute pain can contribute to the development of persistent surgical
      pain. Persistent postsurgical pain has been demonstrated to be clinically relevant in 10% to
      50% of patients undergoing various common operations, including breast cancer surgery. The
      pathogenic mechanisms are multiple, including nerve damage related to surgical technique
      resulting in risk of intercostobrachial neuralgia, neuroma pain, or phantom breast pain.
      Multimodal analgesic strategies are important.Glucocorticoid steroids can also provide
      beneficial effects when administered in appropriate doses as part of a multimodal analgesic
      regimen in the perioperative setting. A recent study demonstrated that preoperative
      application of dexamethasone reduced postoperative nausea and vomiting and pain in patients
      after thyroidectomy.. It is possible that the already established reduction in prostaglandin
      synthesis mediated by dexamethasone contributes to the analgesia. And also there are a lot of
      mechanisms more.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Persistent Surgical Pain on visual analogue scale (VAS).</measure>
    <time_frame>Postoperative 3 months</time_frame>
    <description>At 3.month persistent surgical pain will be evaluated using (visual analogue scale=VAS) (score ranges from O (no pain) to 10 (worst possible pain) . The difference between these VAS scores will be evaluated statistically.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Acute Postsurgical Pain on visual analogue scale (VAS).</measure>
    <time_frame>Postoperative 24 hours</time_frame>
    <description>0.h, 1.h, 2.h, 4.h, 8.h, 12.h, 24.h (visual analogue scale=VAS) (score ranges from O (no pain) to 10 (worst possible pain) postoperative pain will be evaluated in the acute 24 h postoperative period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment-Related Adverse Events</measure>
    <time_frame>Postoperative 24 hours</time_frame>
    <description>For postoperative 24 hours (0.h, 1.h, 2.h, 4.h, 8.h, 12.h, 24.h) adverse events (Bradycardia, hypertension, headache, respirator depression, cough, bronchospasm) will be evaluated. At the end of this, all of the adverse events will be assessed statistically.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Mastectomy, Modified Radical</condition>
  <arm_group>
    <arm_group_label>0.1 mg/kg dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 mg/kg dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>1 hour before surgery</description>
    <arm_group_label>0.1 mg/kg dexamethasone</arm_group_label>
    <arm_group_label>0.2 mg/kg dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years old, female patients

          -  Written informed consent.

        Exclusion Criteria:

          -  American Society of Anesthesiologists Physical Status ˂3

          -  Any contraindication to dexamethasone

          -  Emergency or urgent procedure

          -  Obesity body mass index ≥27 kg m2

          -  Motion sickness and vertigo patients

          -  Axis I psychiatric disease (major depressive disorder, bipolar disorder,
             schizophrenia, etc.)

          -  Significant hepatic (Alanine aminotransferase or Aspartate aminotrans &gt; 2 times
             normal)

          -  Renal (serum creatinine &gt; 2 mg/dl) impairment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Onur Koyuncu, Assist.Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mustafa Kemal University</affiliation>
  </overall_official>
  <reference>
    <citation>Worni M, Schudel HH, Seifert E, Inglin R, Hagemann M, Vorburger SA, Candinas D. Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg. 2008 Dec;248(6):1060-6. doi: 10.1097/SLA.0b013e31818c709a.</citation>
    <PMID>19092351</PMID>
  </reference>
  <reference>
    <citation>Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 2008 Aug 19;99(4):604-10. doi: 10.1038/sj.bjc.6604534.</citation>
    <PMID>18682712</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>September 15, 2015</last_update_submitted>
  <last_update_submitted_qc>September 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mustafa Kemal University</investigator_affiliation>
    <investigator_full_name>Onur Koyuncu</investigator_full_name>
    <investigator_title>Assist.Prof</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>mastectomy</keyword>
  <keyword>persistent surgical pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

